SHPH (Shuttle Pharmaceuticals Holdings) Piotroski F-Score: 3 (As of Jun. 28, 2026) — 50% Above Median


SHPH Shuttle Pharmaceuticals Holdings Inc SHPH
24 GF Score
Price $3.98
! 1 Warning Sign
View Full Analysis

What is Shuttle Pharmaceuticals Holdings Piotroski F-Score?

Shuttle Pharmaceuticals Holdings SHPH +6.35% 24 Piotroski F-Score is 3 as of Jun. 28, 2026, which is 50% above its 10-year median of 2.00. GuruFocus rates SHPH with a GF Score™ of 24/100. The stock has 1 warning sign investors should review. Among 981 Drug Manufacturers companies, Shuttle Pharmaceuticals Holdings ranks worse than 78.29% on this metric.

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Shuttle Pharmaceuticals Holdings has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Shuttle Pharmaceuticals Holdings's Piotroski F-Score or its related term are showing as below:

SHPH' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 2   Max: 4
Current: 3

During the past 6 years, the highest Piotroski F-Score of Shuttle Pharmaceuticals Holdings was 4. The lowest was 1. And the median was 2.

Shuttle Pharmaceuticals Holdings  (NAS:SHPH) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Shuttle Pharmaceuticals Holdings Piotroski F-Score Related Terms


Shuttle Pharmaceuticals Holdings Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Shuttle Pharmaceuticals Holdings's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shuttle Pharmaceuticals Holdings Piotroski F-Score Chart

Shuttle Pharmaceuticals Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial N/A 4.00 2.00 1.00 2.00

Shuttle Pharmaceuticals Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.00 2.00 2.00 2.00 3.00

SHPH vs PRFX, CBIH, UPC: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Shuttle Pharmaceuticals Holdings's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shuttle Pharmaceuticals Holdings Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shuttle Pharmaceuticals Holdings's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Shuttle Pharmaceuticals Holdings's Piotroski F-Score falls into.


SHPH
24GF Score
Shuttle Pharmaceuticals Holdings Inc SHPH
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -3.706 + -2.347 + -2.615 + -2.152 = $-10.82 Mil.
Cash Flow from Operations was -3.355 + -2.627 + -0.973 + -2.417 = $-9.37 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(5.31 + 5.504 + 3.543 + 10.476 + 11.809) / 5 = $7.3284 Mil.
Total Assets at the begining of this year (Mar25) was $5.31 Mil.
Long-Term Debt & Capital Lease Obligation was $0.13 Mil.
Total Current Assets was $2.46 Mil.
Total Current Liabilities was $8.31 Mil.
Net Income was -2.031 + -3.784 + -1.598 + -3.053 = $-10.47 Mil.

Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(4.754 + 2.813 + 0.674 + 2.506 + 5.31) / 5 = $3.2114 Mil.
Total Assets at the begining of last year (Mar24) was $4.75 Mil.
Long-Term Debt & Capital Lease Obligation was $0.22 Mil.
Total Current Assets was $4.96 Mil.
Total Current Liabilities was $1.78 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Shuttle Pharmaceuticals Holdings's current Net Income (TTM) was -10.82. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Shuttle Pharmaceuticals Holdings's current Cash Flow from Operations (TTM) was -9.37. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-10.82/5.31
=-2.03766478

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-10.466/4.754
=-2.20151451

Shuttle Pharmaceuticals Holdings's return on assets of this year was -2.03766478. Shuttle Pharmaceuticals Holdings's return on assets of last year was -2.20151451. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Shuttle Pharmaceuticals Holdings's current Net Income (TTM) was -10.82. Shuttle Pharmaceuticals Holdings's current Cash Flow from Operations (TTM) was -9.37. ==> -9.37 > -10.82 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=0.134/7.3284
=0.01828503

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=0.22/3.2114
=0.06850595

Shuttle Pharmaceuticals Holdings's gearing of this year was 0.01828503. Shuttle Pharmaceuticals Holdings's gearing of last year was 0.06850595. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=2.463/8.306
=0.29653263

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=4.959/1.782
=2.78282828

Shuttle Pharmaceuticals Holdings's current ratio of this year was 0.29653263. Shuttle Pharmaceuticals Holdings's current ratio of last year was 2.78282828. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Shuttle Pharmaceuticals Holdings's number of shares in issue this year was 0.503. Shuttle Pharmaceuticals Holdings's number of shares in issue last year was 0.04. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0/0
=

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0/0
=

Shuttle Pharmaceuticals Holdings's gross margin of this year was . Shuttle Pharmaceuticals Holdings's gross margin of last year was . ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=0/5.31
=0

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=0/4.754
=0

Shuttle Pharmaceuticals Holdings's asset turnover of this year was 0. Shuttle Pharmaceuticals Holdings's asset turnover of last year was 0. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+0+0+0+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Shuttle Pharmaceuticals Holdings has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 3 mean?
Shuttle Pharmaceuticals Holdings (SHPH) has a Piotroski F-Score of 3 as of Jun. 28, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Shuttle Pharmaceuticals Holdings and its competitors. This is 50% above median its historical median of 2.00. Over the past decade, Shuttle Pharmaceuticals Holdings' Piotroski F-Score has ranged from 1.00 to 4.00. According to the industry distribution chart, Shuttle Pharmaceuticals Holdings ranks #768 out of 981 companies in the Drug Manufacturers industry, placing it in the top 78.3%.
Is Shuttle Pharmaceuticals Holdings' Piotroski F-Score too high?
Shuttle Pharmaceuticals Holdings' current Piotroski F-Score of 3 is 50% above median its 10-year median of 2.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 4.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Shuttle Pharmaceuticals Holdings' value of 3 is 40% below this industry median. Based on the distribution chart, Shuttle Pharmaceuticals Holdings ranks #768 out of 981 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Shuttle Pharmaceuticals Holdings has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Shuttle Pharmaceuticals Holdings' Piotroski F-Score compare to PRFX and CBIH?
According to the Drug Manufacturers industry distribution chart, Shuttle Pharmaceuticals Holdings ranks #768 out of 981 companies for Piotroski F-Score. This places Shuttle Pharmaceuticals Holdings in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Shuttle Pharmaceuticals Holdings' value of 3 is 40% below this benchmark. Historically, Shuttle Pharmaceuticals Holdings' own Piotroski F-Score has ranged from 1.00 to 4.00 over the past decade. While the company's 10-year median is 2.00 vs. the industry median of 5.00, Shuttle Pharmaceuticals Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shuttle Pharmaceuticals Holdings's current Piotroski F-Score of 3 is 40% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Shuttle Pharmaceuticals Holdings and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shuttle Pharmaceuticals Holdings's current Piotroski F-Score is 3, which is 50% above median its own 10-year median of 2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shuttle Pharmaceuticals Holdings stock overvalued right now?
Shuttle Pharmaceuticals Holdings (SHPH) has a current Piotroski F-Score of 3. The current Piotroski F-Score is 3, which is 50% above median its 10-year median of 2.00 and 40% below the Drug Manufacturers industry median of 5.00. Shuttle Pharmaceuticals Holdings' overall GF Score™ is 24/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Shuttle Pharmaceuticals Holdings (SHPH), the current Piotroski F-Score is 3 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Shuttle Pharmaceuticals Holdings Business Description

Address 401 Professional Drive, Suite 260, Gaithersburg, MD, USA, 20879
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. Its pipeline includes: Ropidoxuridine, HDAC Inhibitors, PSMA-B, and PC-Rad Test.
24GF Score

Get the complete analysis for SHPH

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.98
Price